Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or Medulloblastoma
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Cellectar Biosciences, Inc.
University of California, San Francisco
City of Hope Medical Center
Children's Oncology Group
Children's Oncology Group
Dana-Farber Cancer Institute
M.D. Anderson Cancer Center
University of Pittsburgh
Dana-Farber Cancer Institute
Augusta University
The University of Texas Health Science Center, Houston
Jazz Pharmaceuticals
University of Florida
Seattle Children's Hospital
Seattle Children's Hospital
M.D. Anderson Cancer Center
Cedars-Sinai Medical Center
Plus Therapeutics
Hackensack Meridian Health
Thomas Jefferson University
Ann & Robert H Lurie Children's Hospital of Chicago
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
St. Jude Children's Research Hospital
Istari Oncology, Inc.
The Hospital for Sick Children
University of Alabama at Birmingham
National Institutes of Health Clinical Center (CC)
Bexion Pharmaceuticals, Inc.
Bexion Pharmaceuticals, Inc.
M.D. Anderson Cancer Center
Case Comprehensive Cancer Center
Lumos Pharma
Emory University
National Institutes of Health Clinical Center (CC)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Medical College of Wisconsin
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
City of Hope Medical Center
City of Hope Medical Center
Masonic Cancer Center, University of Minnesota
Masonic Cancer Center, University of Minnesota
City of Hope Medical Center
St. Jude Children's Research Hospital
Duke University
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Indiana University